Article
Oncology
Chen Yuan, Xuehong Zhang, Ana Babic, Vicente Morales-Oyarvide, Yin Zhang, Stephanie A. Smith-Warner, Kana Wu, Molin Wang, Brian M. Wolpin, Jeffrey A. Meyerhardt, Andrew T. Chan, Frank B. Hu, Charles S. Fuchs, Shuji Ogino, Edward L. Giovannucci, Kimmie Ng
Summary: Among patients with colorectal cancer, preexisting diabetes was associated with increased risk of long-term mortality, particularly from other malignancies and cardiovascular disease. The impact of diabetes on survival varied by sex, with women showing a modest increase in overall mortality in the first 5 years after cancer diagnosis. Beyond 5 years, both men and women with diabetes at diagnosis had substantially increased overall mortality.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2021)
Letter
Gastroenterology & Hepatology
Jan Dimberg, Levar Shamoun, Kalle Landerholm, Dick Wagsaeter
Summary: The association between type 2 diabetes mellitus (DM) and colorectal cancer (CRC) has been investigated, with reports suggesting an increased risk of CRC in DM patients. Metformin, with its anti-inflammatory effects, may protect against the development of CRC in DM patients and improve prognosis. However, in this cohort study, there were no associations between the presence of DM or metformin and cancer specific survival, plasma levels of inflammatory factors or irisin. A specific single nucleotide polymorphism in the insulin-like growth factor binding protein 7 gene was associated with DM in CRC patients.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Multidisciplinary Sciences
Zeinab Tarhini, Kamelia Manceur, Julien Magne, Muriel Mathonnet, Jeremy Jost, Niki Christou
Summary: The study examined the associations between metformin use and overall survival (OS) and disease-free survival (DFS) in colorectal cancer (CRC) patients with type 2 diabetes mellitus (DM). The findings suggest that metformin use may improve OS and DFS in CRC patients with type 2 DM.
SCIENTIFIC REPORTS
(2022)
Article
Medicine, General & Internal
Jessica J. P. Shami, Vincent K. C. Yan, Yue Wei, Hassan Alwafi, Joseph E. Blais, Eric Wan, Carlos K. H. Wong, Ka Shing Cheung, Wai K. Leung, Martin C. S. Wong, Ian C. K. Wong, Esther W. Chan
Summary: The concurrent use of low-dose aspirin and metformin was not associated with a lower risk of colorectal cancer in patients with type 2 diabetes mellitus.
JOURNAL OF INTERNAL MEDICINE
(2023)
Article
Oncology
Kai Wang, Wenjie Ma, Yang Hu, Markus Dines Knudsen, Long H. Nguyen, Kana Wu, Kimmie Ng, Molin Wang, Shuji Ogino, Qi Sun, Edward L. Giovannucci, Andrew T. Chan, Mingyang Song
Summary: Current recommendations for colorectal cancer screening do not take into account the presence of type 2 diabetes (T2D). This study found that the absolute benefit of endoscopic screening for colorectal cancer prevention may be higher for individuals with T2D compared to those without T2D. Additionally, individuals with T2D reached the threshold risk level for colorectal cancer at a younger age than those without T2D, suggesting the consideration of earlier endoscopic screening in individuals with T2D.
CANCER PREVENTION RESEARCH
(2022)
Article
Oncology
Yong-Moon Mark Park, Dale P. Sandler
Summary: The relationship between type 2 diabetes, metformin, and breast cancer is intricate. While T2D may increase the risk, metformin as a primary treatment option for T2D could potentially decrease the risk of breast cancer. Research efforts are focused on untangling the effects of T2D and metformin use on breast cancer risk in a prospective study.
BRITISH JOURNAL OF CANCER
(2021)
Article
Oncology
Alessandro Ottaiano, Luisa Circelli, Mariachiara Santorsola, Giovanni Savarese, Daniela Fontanella, Valerio Gigantino, Annabella Di Mauro, Maurizio Capuozzo, Silvia Zappavigna, Angela Lombardi, Francesco Perri, Marco Cascella, Vincenza Granata, Guglielmo Nasti, Michele Caraglia
Summary: This study investigated the prognostic and genetic interactions between type 2 diabetes and metastatic colorectal cancer, finding that diabetes is a negative prognostic factor for survival in colorectal cancer patients. Gene variants associated with diabetes and cancer may coincide, providing a basis for innovative models of tumor progression and therapy.
MOLECULAR ONCOLOGY
(2022)
Article
Oncology
Y-M M. Park, D. B. Bookwalter, K. M. O'Brien, C. L. Jackson, C. R. Weinberg, D. P. Sandler
Summary: The study found that type 2 diabetes is associated with an increased risk of breast cancer, but the risk may be reduced with the use of metformin, particularly for estrogen receptor-positive breast cancer.
ANNALS OF ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Tianli Hui, Chao Shang, Liu Yang, Meiqi Wang, Ruoyang Li, Zhenchuan Song
Summary: Early reports suggest that the drug metformin, used to treat T2DM, may have a positive impact on the prognosis of cancer. A study on Chinese breast cancer patients with T2DM found that those using metformin showed improved disease-free and overall survival compared to those not using the drug.
SCIENTIFIC REPORTS
(2021)
Article
Clinical Neurology
Huan Yu, Ruotong Yang, Junhui Wu, Siyue Wang, Xueying Qin, Tao Wu, Yonghua Hu, Yiqun Wu
Summary: This study suggests that metformin is associated with a lower risk of depression. When compared with other oral hypoglycemic agents, the metformin group had a reduced incidence of depression.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Review
Pharmacology & Pharmacy
Jixue Tan, Yang Wang, Song Liu, Qingyang Shi, Xu Zhou, Yiling Zhou, Xiaoling Yang, Pingshan Chen, Sheyu Li
Summary: A systematic review comparing the effectiveness, safety, and patient compliance between metformin immediate-release (IR) and extended-release (XR) formulations found no significant differences in outcomes. However, metformin XR was associated with improved patient compliance compared to metformin IR.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Endocrinology & Metabolism
Chin-Hsiao Tseng
Summary: The study found that there is a significantly lower risk of primary bone cancer in patients with type 2 diabetes mellitus who adhere to metformin treatment, especially in men aged over 60 years.
Article
Multidisciplinary Sciences
Magdolna Herold, Attila Marcell Szasz, Gyongyver Szentmartoni, Emoke Martinek, Viktor Madar-Dank, Andras Jozsef Barna, Reka Mohacsi, Aniko Somogyi, Magdolna Dank, Zoltan Herold
Summary: Type 2 diabetes mellitus is a progressive disease that affects colorectal cancer survival. However, there is limited and controversial data on the relationship between CRC survival and T2DM duration. This retrospective observational study highlights the significant impact of T2DM duration on CRC survival, emphasizing the need for closer follow-up for this subgroup.
SCIENTIFIC REPORTS
(2023)
Article
Multidisciplinary Sciences
Magdolna Herold, Attila Marcell Szasz, Gyongyver Szentmartoni, Emoke Martinek, Viktor Madar-Dank, Andras Jozsef Barna, Reka Mohacsi, Aniko Somogyi, Magdolna Dank, Zoltan Herold
Summary: This study found that the duration of type 2 diabetes significantly affects the survival rate of colorectal cancer patients, suggesting the need for closer follow-up.
SCIENTIFIC REPORTS
(2023)
Review
Oncology
Francesco Melia, Palita Udomjarumanee, Dmitry Zinovkin, Nahid Arghiani, Md Zahidul Islam Pranjol
Summary: Colorectal cancer is the second leading cause of cancer-related mortality worldwide and is still considered incurable in advanced stages. Age-related cellular senescence and type 2 diabetes are known risk factors for CRC development, with recent findings suggesting a potential link between type 2 diabetes-induced premature cell senescence and CRC tumorigenesis.
FRONTIERS IN ONCOLOGY
(2022)